Industry

AIBN was established with the specific aim of combining research excellence with an industry focus.

The commercial objectives of the Institute are to:

Produce innovations assisting in the growth of industries;
Develop new products, processes and technologies; and
To play a major role in developing the Australian nanotechnology and biotechnology industries, through establishing new opportunities, obtaining the support of the industry sector and interfacing with industrial collaborators.

AIBN has worked to develop and promote:

A culture of commercialisation within the Institute;
Strategies to support the Institute’s commercialisation and industry engagement;
The Institute’s R&D capabilities and infrastructure to industry; and
A suite of quality patent assets relevant to industry and market need.

Continuing Professional Development

Industrial relevance

How we work with industry

COVID-killing coating a spray away

Published on: 15 September 2021

An antiviral surface coating technology sprayed on face masks could provide an extra layer of protection against COVID-19 and the flu.
Needle-free COVID-19 vaccine shows promise

Published on: 4 June 2021

Needle-free technology, originally developed at the AIBN, has been used to administer a COVID-19 vaccine candidate to successfully protect mice, demonstrating the potential of non-invasive delivery.
UQ technology powers up greener alternative to lithium ion in Brisbane manufacturing deal

Published on: 23 April 2021

Faster-charging and more sustainable batteries with a life up to three times greater than lithium ion are being built with technology developed at AIBN.
UQ congratulates startup Vaxxas on $30M partnership with US government

Published on: 13 October 2020

A startup company developing technology based on University of Queensland (UQ) research has announced it will partner with the US Government to test its needle-free vaccine delivery technology.
New funding boosts potential therapy for immune disorders

Published on: 6 November 2019

An antibody that could treat immune system disorders could be on the path to clinical trials after securing $20 million in Series A funding.
Start-up makes quick work of cellular experiments

Published on: 6 February 2017

Start-up company Scaled Biolabs Inc is changing the way researchers around the world conduct manual cellular experiments and accelerating discoveries in biology by providing novel devices that enable 1000’s of experiments to occur simultaneously.
UQ-Amyris collaboration seeks to accelerate development of Queensland ‘Biofutures Hub’

Published on: 7 June 2016

Leading American biotechnology company Amyris, Inc. and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland have signed a Memorandum of Understanding to support the development of a Queensland-based biotechnology industry using feedstock from local sugarcane.
New $4.5 million facility opens doors to stronger collaboration

Published on: 16 January 2014

A new facility for enzyme formulation and production has been opened, strengthening a collaboration between the Australian Institute for Bioengineering and Nanotechnology and industry partner Bioproton.